<DOC>
	<DOCNO>NCT02034916</DOCNO>
	<brief_summary>The purpose 2-stage , 2-cohort Phase 2 trial evaluate safety efficacy talazoparib ( also know BMN 673 ) subject locally advance metastatic breast cancer deleterious germline BRCA 1 BRCA 2 mutation . Subjects assign either Cohort 1 2 base prior chemotherapy metastatic disease : - Cohort 1 ) Subjects document PR CR prior platinum-containing regimen metastatic disease disease progression &gt; 8 week follow last dose platinum ; - Cohort 2 ) Subjects receive &gt; 2 prior chemotherapy regimens metastatic disease prior platinum therapy metastatic disease</brief_summary>
	<brief_title>A Phase 2 , 2-Stage , 2-Cohort Study Talazoparib ( BMN 673 ) , Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation ( ABRAZO Study )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>Histologically cytologically confirm carcinoma breast Locally advance and/or metastatic disease Deleterious pathogenic germline BRCA 1 BRCA 2 mutation Prior chemotherapy : Cohort 1 ) PR CR prior platinumcontaining regimen metastatic disease disease progression &gt; 8 week follow last dose platinum ; Cohort 2 ) &gt; 2 prior chemotherapy regimens metastatic disease prior platinum metastatic disease ECOG performance status â‰¤ 1 Have adequate organ function Prior enrollment clinical trial PARP inhibitor CNS metastasis except adequately treat brain metastasis document baseline CT MRI scan progress since previous scan require corticosteroids management CNS symptoms Prior malignancy except prior BRCAassociated cancer long current evidence prior cancer , carcinoma situ cervix nonmelanoma skin cancer , cancer diagnose definitively treat &gt; 5 year prior study enrollment subsequent evidence recurrence Known HIV positive , active hepatitis C virus , active hepatitis B virus Known hypersensitivity component talazoparib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>BRCA mutation</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>BRCA 1</keyword>
	<keyword>BRCA 2</keyword>
</DOC>